In the competitive landscape of pharmaceutical manufacturing, the quality and efficiency of sourcing essential chemical intermediates are critical differentiators. NINGBO INNO PHARMCHEM CO.,LTD. stands out as a premier supplier, offering a comprehensive range of high-purity compounds that facilitate the development of life-saving medications. Our expertise is particularly evident in providing key intermediates for targeted therapies, such as the vital precursor for Abemaciclib.

The compound 5-[ (4-Ethyl-1-Piperazinyl) Methyl]-2-Pyridinamine, identified by CAS No. 1180132-17-5, is a cornerstone in the synthesis of Abemaciclib, a crucial drug for patients battling advanced breast cancer. NINGBO INNO PHARMCHEM CO.,LTD.'s dedication to excellence ensures that our Abemaciclib intermediate synthesis processes yield a product that meets the highest purity standards, making it a reliable pharmaceutical intermediate for cancer drugs.

We offer this essential building block as a high purity liquid chemical intermediate (>98%), recognizing that even minute impurities can impact the final API. This commitment to quality extends to our role as a supplier of critical CAS 1180132-17-5 for various research and production needs. Whether it’s for established API production workflows or novel drug development, our intermediates are designed for optimal performance.

For research laboratories, the availability of consistent and pure chemical compounds for research is non-negotiable. NINGBO INNO PHARMCHEM CO.,LTD. also provides bespoke custom chemical synthesis for pharma services, allowing clients to obtain tailored chemical solutions for their specific projects. Our role as a dependable provider of laboratory reagent 1180132-17-5 supports the foundational work that leads to significant medical advancements.

The NINGBO INNO PHARMCHEM CO.,LTD. advantage lies in our unwavering focus on quality, reliability, and customer support. By providing essential intermediates like 5-[ (4-Ethyl-1-Piperazinyl) Methyl]-2-Pyridinamine, we empower our partners to innovate faster, develop more effective treatments, and ultimately contribute to better patient outcomes in the field of oncology and beyond.